ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014
RIG-I receptors induced by dsRNA challenges in an HDM-mouse model of asthma exacerbation Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014
The immunomodulatory activity of protein S protects against allergic airway inflammation Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Transient receptor potential channels in a mouse model of isocyanate-induced airway hyperresponsiveness Source: International Congress 2014 – Mechanistic murine studies of asthma and lung inflammation Year: 2014
Dose-dependent differential effects of thrombin in allergic bronchial asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013
Anti-IgE as an alternative treatment for occupational asthma due to low molecular weight agents Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods Year: 2016
Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
PI3Kδ inhibition confer efficacy in experimental models of allergic airway inflammation Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Bcl-2 antagonist ABT-737 attenuates corticosteroid-insensitive neutrophilic airway inflammation Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Effect of retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Characterisation of a steroid-insensitive severe asthma model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Andrographolide restores steroid sensitivity to block LPS/IFN-γ-induced IL-27 and airway hyperresponsiveness in mice Source: International Congress 2015 – New models for treating airway diseases Year: 2015
Effects of LTRA on T cell-induced bronchoconstriction in the mice Source: International Congress 2015 – New models for treating airway diseases Year: 2015
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014